Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy

Laith Farah Al-Rabadi, Tiffany Caza, Claire Trivin-Avillach, Aylin R. Rodan, Nicole Andeen, Norifumi Hayashi, Brandi Williams, Monica P. Revelo, Fred Clayton, Jo Abraham, Edwin Lin, Willisa Liou, Chang Jiang Zou, Nirupama Ramkumar, Tim Cummins, Daniel W. Wilkey, Issa Kawalit, Christian Herzog, Aaron Storey, Rick EdmondsonRonald Sjoberg, Tianxin Yang, Jeremy Chien, Michael Merchant, John Arthur, Jon Klein, Chris Larsen, Laurence H. Beck

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%-20% of patients. Methods A multipronged approach, using traditional and modern technologies, converged on a novel target antigen, and capitalized on the temporal variation in autoantibody titer for biomarker discovery. Immunoblotting of human glomerular proteins followed by differential immunoprecipitation and mass spectrometric analysis was complemented by laser-capture microdissection followed by mass spectrometry, elution of immune complexes from renal biopsy specimen tissue, and autoimmune profiling on a protein fragment microarray. Results These approaches identified serine protease HTRA1 as a novel podocyte antigen in a subset of patients with primary MN. Sera from two patients reacted by immunoblotting with a 51-kD protein within glomerular extract and with recombinant human HTRA1, under reducing and nonreducing conditions. Longitudinal serum samples from these patients seemed to correlate with clinical disease activity. As in PLA2R- and THSD7A- associated MN, anti-HTRA1 antibodies were predominantly IgG4, suggesting a primary etiology. Analysis of sera collected during active disease versus remission on protein fragment microarrays detected significantly higher titers of anti-HTRA1 antibody in active disease. HTRA1 was specifically detected within immune deposits of HTRA1-associated MN in 14 patients identified among three cohorts. Screening of 118 “quadruple-negative” (PLA2R-, THSD7A-, NELL1-, EXT2-negative) patients in a large repository of MN biopsy specimens revealed a prevalence of 4.2%. Conclusions Conventional and more modern techniques converged to identify serine protease HTRA1 as a target antigen in MN.

Original languageEnglish (US)
Pages (from-to)1666-1681
Number of pages16
JournalJournal of the American Society of Nephrology
Volume32
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy'. Together they form a unique fingerprint.

Cite this